Trial Profile
A randomised, double-blind, 4-weeks cross-over trial to investigate the effect of 500 µg roflumilast tablets once-daily versus placebo on pulmonary function, asthma symptoms and inflammatory markers in subjects with asthma not adequately controlled with a combination of at least medium dose ICS/LABA maintenance therapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2013
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Asthma
- Focus Biomarker; Therapeutic Use
- Sponsors Takeda Pharmaceuticals International GmbH
- 22 Feb 2012 New trial record